Sulphonylurea treatment of NIDDM patients with cardiovascular disease: A mixed blessing?

Diabetologia

Volumn 39, Issue 5, 1996, Pages 503-514

  Leibowitz, G ^a   Cerasi, E ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

arrhythmia; atherosclerosis; cardiovascular disease; impaired glucose tolerance; K+(ATP) channels; myocardial ischaemia; non insulin dependent diabetes mellitus; preconditioning; risk factors; sulphonylurea

Indexed keywords

ACETOHEXAMIDE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; POTASSIUM CHANNEL; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE;

ANIMAL; ATHEROSCLEROSIS; HEART MUSCLE ISCHEMIA; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029916829     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00403296     Document Type: Review

References (140)

1. Gerich J (1989) Drug therapy - oral hypoglycemic agents. N Engl J Med 321: 1231-1245
2. Lebovitz H (1994) Oral antidiabetic agents. In: Kahn CR, Weir GC (eds) Joslin's diabetes mellitus, 13th ed. Lea & Febiger, Philadelphia, pp 508-529
3. Anonymous (1970) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 25: 1129-1153
4. Kolata G (1979) Controversy over study of diabetes drugs continues for nearly a decade. Science 203: 986-990
5. Schor S (1971) The University Group Diabetes Program: a statistician looks at the mortality results. J Am Med Assoc 217: 1673-1675
6. Seltzer H (1972) A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 21: 976-979
7. Kilo C, Miller L, Williamson J (1980) The crux of the UGDP: spurious results and biologically inappropriate data analysis. Diabetologia 18: 179-185
8. +-channels in cardiac muscle. Nature 305: 147-148
9. + -channels in arterial smooth muscle. Science 245: 177-180
10. Sturgess N, Kozlowski R, Carrington C, Hales C, Ashford M (1988) Effects of sulfonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin-secreting cell line. Br J Pharmacol 95: 83-94
11. + channels. J Biol Chem 263: 7933-7936
12. Grover G, McCullough J, Henry D, Conder M, Sleph P (1989) Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide. J Pharmacol Exp Therap 251: 98-104
13. + channels protect the myocardium against ischemic/reperfusion damage. Circ Res 69: 571-581
14. + channels involves high energy phosphate preservation. Am J Physiol 265: H1809-H1818
15. ATP channels: an endogenous protective mechanism during repetitive ischemia. Am J Physiol 264: H495-H504
16. Hofmann D, Opie L (1993) Potassium channel blockade and acute myocardial infarction: implications for management of the non-insulin requiring diabetic patient. Eur Heart J 14: 1585-1589
17. Auchampach J, Maruyama M, Gross G (1994) Cardioprotective actions of potassium channel openers. Eur Heart J 15 [Suppl]: C89-C94
18. Grover G, Dzwonczyk S, Parham C, Sleph P (1990) The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs. Cardiovasc Drugs Ther 4: 465-474
19. Schulz R, Rose J, Heusch G (1994) Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine. Am J Physiol 267: H1341-H1352
20. Lee C (1994) Gating mechanisms of ATP sensitive potassium channels: implication in reperfusion injury and preconditioning. Cardiovasc Res 28: 729-734
21. Smits P, Thien T (1995) Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM? Diabetologia 38: 116-121
22. Sargent C, Smith M, Dzwonczyk S, Sleph P Grover G (1991) Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents. J Pharmacol Exp Therap 259: 97-103
23. Auchampach J, Grover G, Gross G (1992) Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate. Cardiovasc Res 26: 1054-1062
24. Galinanes M, Shattock M, Hearse D (1992) Effects of potassium channel modulation during global ischaemia in isolated rat heart with and without cardioplegia. Cadiovasc Res 26: 1063-1068
25. Gross G, Auchampach J (1992) Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 70: 223-233
26. + channels on ECG ST segment elevation during a bout of myocardial ischemia. A study on epicardial mapping in dogs. Circulation 88: 1845-1851
27. Opie LH (1993) Modulation of ischemia by regulation of the ATP-sensitive potassium channel. Cardiovasc Drugs Ther 7 [Suppl 3]: 507-513
28. Thornton JD, Thornton CS, Sterling DL, Downey JM (1993) Blockade of ATP-sensitive potassium channels increases infarct size but does not prevent preconditioning in rabbit hearts. Circ Res 72: 44-49
29. Toombs CF, McGee DS, Johnston WE, Vinten Johansen J (1993) Protection from ischaemic-reperfusion injury with adenosine pretreatment is reversed by inhibition of ATP sensitive potassium channels. Cardiovasc Res 27: 623-629
30. Toombs CF, Moore TL, Shebuski RJ (1993) Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc Res 27: 617-622
31. Edwards G, Weston A (1990) Potassium channel openers and vascular smooth muscle relaxation. Pharmacol Ther 48: 237-258
32. Katz A (1993) Cardiac ion channels. N Engl J Med 328: 1244-1251
33. Nichols C, Lederer W (1991) Adenosine triphosphate sensitive potassium channels in the cardiovascular system. Am J Physiol 261: H1675-H1686
34. Keung E, Li Q (1991) Lactate activates ATP-sensitive potassium channels in guinea pig ventricular myocytes. J Clin Invest 88: 1772-1777
35. + channels in feline ventricular myocytes. Am J Physiol 261: H755-H761
36. ATP channels, and ischemic preconditioning in dogs. Am J Physiol 264: H1327-H1336
37. + channels to A1 receptors by G proteins in rat ventricular myocytes. Am J Physiol 259: H820-H826
38. ATP channel. Am J Physiol 266: H829-H839
39. Gross GJ, Yao Z, Pieper GM, Auchampach JA (1994) The ATP-regulated potassium channel in ischemia-reperfusion injury. Ann N Y Acad Sci 723: 71-81
40. Coetzee WA (1992) ATP-sensitive potassium channels and myocardial ischemia: why do they open? Cardiovasc Drug Ther 6: 201-208
41. Sanguinetti MC (1992) Modulation of potassium channels by antiarrhythmic and hypertensive drugs. Hypertension 19: 228-236
42. Brayden JE (1991) Hyperpolarization and relaxation of resistance arteries in response to adenosine diphosphate. Circ Res 69: 1415-1420
43. Daut J, Maier-Rudolph W, von Beckerath N, Mehrke G, Gunther K, Goedel-Meinen L (1990) Hypoxic dilatation of coronary arteries is mediated by ATP-sensitive potassium channels. Science 247: 1341-1344
44. Wolleben CD, Sanguinetti MC, Siegl PK (1989) Influence of ATP-sensitive potassium channel modulators on ischemia-induced fibrillation in isolated rat hearts. J Mol Cell Cardiol 21: 783-788
45. Belardinelli L, Linden J, Berne RM (1989) The cardiac effects of adenosine. Prog Cardiovasc Dis 32: 73-97
46. Wainwright CL, Parrat JR (1988) An antiarrhythmic effect of adenosine during myocardial ischemia and reperfusion. Eur J Pharmacol 145: 183-194
47. Edlund A, Siden A, Sollevi A (1987) Evidence for an anti-aggregatory effect of adenosine at physiological concentration and for its role in the action of dipyridamole. Thromb Res 45: 183-190
48. Smits P, Lenders JWM, Willemsen JJ, Thien T (1991) Adenosine attenuates the response to sympathetic stimuli in man. Hypertension 18: 216-223
49. Murray CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136
50. Liu Y, Downey JM (1992) Ischemic preconditioning protects against infarction in rat heart. Am J Physiol 263: H1107-H1112
51. Fralix TA, Steenbergen C, London RE, Murphy E (1993) Glibenclamide does not abolish the protective effect of preconditioning on stunning in the isolated perfused rat heart. Cardiovasc Res 27: 630-637
52. Yellon DM, Alkhulaifi M, Browne EE, Pugsley WB (1992) Ischaemic preconditioning limits infarct size in the rat heart. Cardiovasc Res 26: 983-987
53. Li GC, Vasquez JA, Gallagher KP, Lucchessi BR (1990) Myocardial protection with preconditioning. Circulation 82: 609-619
54. + channel blocker. Circulation 90: 700-705
55. Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW, Herrmann HC, Laskey WK (1990) Adaptation to ischemia during percutaneous transluminal coronary angioplasty: clinical, hemodynamic, and metabolic features. Circulation 82: 2044-2051
56. Cribier A, Corsatz L, Koning R et al. (1992) Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty: a prospective study. J Am Coll Cardiol 20: 578-586
57. Downey JM (1993) An explanation for the reported observation that ATP dependent potassium channel openers mimic preconditioning. Cardiovasc Res 27: 1565
58. Downey JM, Liu GS, Thornton JD (1993) Adenosine and anti-infarct effects of preconditioning. Cardiovasc Res 27: 3-8
59. ATP channels. Circulation 89: 1229-1236
60. + channels in cerebral ischemic preconditioning. Proc Natl Acad Sci 92: 4666-4670
61. Pearson J (1985) Pharmacokinetics of glyburide. Am J Med 79 [Suppl 3B]: 67-71
62. Jackson J, Bressler R (1981) Clinical pharmacology of sulfonylurea hypoglycaemic agents. Drugs 22: 211-245
63. Skillman T, Feldman J (1981) The pharmacology of sulfonylureas. Am J Med 70: 361-372
64. Ferner R, Chaplin S (1987) The relationship between the pharmacokinetics and the pharmacodynamic effects of oral hypoglycaemic drugs. Clin Pharmacokinet 12: 379-401
65. Melander A (1987) Clinical pharmacology of sulfonylureas. Metabolism 36 [Suppl 1]: 12-16
66. Lebovitz H (1983) Clinical utility of oral hypoglycemic agents in the management of patients with noninsulin-dependent diabetes mellitus. Am J Med 75 [Suppl 5B]: 94-99
67. Aguilar-Bryan L, Nichols C, Wechsler S et al. (1995) Cloning of the B cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 268: 423-426
68. Samaha F, Heineman F, Ince C, Fleming J, Balaban R (1992) ATP-sensitive potassium channel is essential to maintain basal coronary vascular tone in vivo. Am J Physiol 262: C1220-C1227
69. Imamura Y, Tomoike H, Narishige T, Takahashi T, Kasuya H, Takeshita A (1992) Glibenclamide decreases basal coronary blood flow in anesthetized dogs. Am J Physiol 263: H399-H404
70. Bril A, Laville MP, Gout B (1992) Effects of glibenclamide on ventricular arrhythmias and cardiac function in ischaemia and reperfusion in isolated rat heart. Cardiovasc Res 26: 1069-1076
71. Aversano T, Ouyang P, Silverman H (1991) Blockade of the ATP-sensitive potassium channel modulates reactive hyperemia in the canine coronary circulation. Circ Res 69: 618-622
72. Belloni FL, Hintze TH (1991) Glibenclamide attenuates adenosine induced bradycardia and coronary vasodilatation. Am J Physiol 261: H720-H727
73. Nakae I, Quan L, Sugimoto Y, Tsutamoto T, Kinoshita M (1994) Glibenclamide-induced oscillation of canine coronary artery is independent of myocardial ischemia. J Cardiovasc Pharmacol 23: 473-479
74. ATP channels in coronary vasodilation during exercise. Circulation 88: 1245-1253
75. ATP channel blockade. J Clin Invest 95: 285-295
76. Kosmas EN, Levy RD, Hussain SNA (1995) Acute effects of glyburide on the regulation of peripheral blood flow in normal humans. Eur J Pharmacol 274: 193-199
77. Chan JC, Tomlinson B, Critchley JA, Cockram CS, Walden RJ (1993) Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 16: 1035-1038
78. + ATP channels in man. Diabetologia 38 [Suppl]: A43 (Abstract)
79. Billman GE, Avendano CE, Halliwill JR, Burroughs JM (1993) The effects of the ATP-dependent potassium channel antagonist, glyburide, on coronary blood flow and susceptibility to ventricular fibrillation in unanesthetized dogs. J Cardiovasc Pharmacol 21: 197-204
80. Mitani A, Kinoshita K, Fukamachi K et al. (1991) Effects of glibenclamide and nicorandil on cardiac function during ischemia and reperfusion in isolated perfused rat hearts. Am J Physiol 261: H1864-H1871
81. + channel opener Aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes. J Pharmacol Exp Ther 259: 961-967
82. Auchampach JA, Maruyama M, Gross GJ (1994) Cardioprotective actions of potassium channel openers. Eur Heart J 15 [Suppl]: C89-C94
83. + channel opening property and nitrate property. Clin Exp Pharmacol Physiol 20: 595-602
84. D'Alonzo AJ, Darbenzio RB, Parham CS, Grover GJ (1992) Effects of intracoronary cromakalim on postischaemic contractile function and action potential duration. Cardiovasc Res 26: 1046-1053
85. Sargent CA, Dzwonczyk S, Grover GJ (1992) Effect of the potassium channel opener EMD 56431 on globally ischemic rat hearts. Pharmacology 45: 260-268
86. Auchampach JA, Cavero I, Gross GJ (1992) Nicorandil attenuates myocardial dysfunction associated with transient ischemia by opening ATP-dependent potassium channels. J Cardiovasc Pharmacol 20: 765-771
87. McCullough JR, Normandin DE, Conder ML, Sleph PG, Dzwonczyk S, Grover GJ (1991) Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate. Circ Res 69: 949-958
88. Offstad J, Kirkeboen KA, Ilebekk A, Downing SE (1994) ATP gated potassium channels in acute myocardial hibernation and reperfusion. Cardiovasc Res 28: 872-880
89. Grover GJ, Dzwonczyk S, Sleph PG, Sargent CA (1993) The ATP-sensitive potassium channel blocker glibenclamide (glyburide) does not abolish preconditioning in isolated ischemic rat hearts. J Pharmacol Exp Ther 265: 559-564
90. Lu H, Remeysen P, De Clerck F (1993) The protection by ischemic preconditioning against myocardial ischemia-and reperfusion-induced arrhythmias is not mediated by ATP-sensitive potassium channels in rats. Coron Artery Dis 4: 649-657
91. ATP channel antagonist to attenuate preconditioning in rabbit myocardium. Cardiovasc Res 28: 1337-1341
92. Shimabukuro M, Nagamine F, Murakami K, Oshiro K, Mimura G (1994) Chronic gliclazide treatment affects basal and post-ischemic cardiac function in diabetic rats. Gen Pharmacol 25: 697-704
93. Tosaki A, Szerdahelyi P, Engelman RM, Das DK (1993) Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts? J Pharmacol Exp Ther 267: 1355-1362
94. Chi L, Black SC, Kuo PI, Fagbemi SO, Lucchesi BR (1993) Actions of pinacidil at a reduced potassium concentration: a direct effect possibly involving the ATP-dependent potassium channel. J Cardiovasc Pharmacol 21: 179-190
95. ATP modulators cromakalim, pinacidil, or glibenclamide on arrhythmias in isolated perfused rat heart subjected to regional ischaemia. Cardiovasc Res 28: 881-887
96. + loss and arrhythmias in rat hearts. Effect of glibenclamide, a sulfonylurea. Circ Res 66: 478-485
97. Vegh A, Komori S, Szekeres L, Parratt JR (1992) Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats. Cardiovasc Res 26: 487-495
98. Hagar JM, Hale SL, Kloner RA (1991) Effect of preconditioning ischemia on reperfusion arrhythmias after coronary artery occlusion and reperfusion in the rat. Circ Res 68: 61-68
99. Vegh A, Papp JG, Szekeres L, Parratt JR (1993) Are ATP sensitive potassium channels involved in the pronounced antiarrhythmic effects of preconditioning? Cardiovasc Res 27: 638-643
100. Kannel W, McGee D (1979) Diabetes and cardiovascular disease. The Framingham Study. J Am Med Ass 241: 2035-2058
101. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H (1980) Cronary heart disease risk and impaired glucose tolerance. The Whitehall study. Lancet I: 1373-1376
102. Yano K, Kagan A, McGee D, Rhoads GG (1982) Glucose intolerance and nine-year mortality in Japanese men in Hawaii. Am J Med 72: 71-80
103. Yamada N, Yoshinaga H, Sakurai N et al. (1994) Increased risk for coronary artery disease in Japanese subjects with hyperinsulinemia or glucose intolerance. Diabetes Care 17: 107-114
104. Sartor G, Scherstén B, Carlström S, Melander A, Nordén A, Persson G (1980) Ten year follow-up of subjects with impaired glucose tolerance. Prevention of diabetes by tolbutamide and diet regulation. Diabetes 29: 41-49
105. Soler N, Bennett M, Lamb P, Pentecost B, FitzGerald M, Malins J (1974) Coronary care for myocardial infarction. Lancet I: 475-477
106. Czyzyk A, Krolewski A, Szablowska S, Alot A, Kopczynski J (1980) Clinical course of myocardial infarction among diabetic patients. Diabetes Care 3: 526-529
107. Soler NG, Bennett MA, Pentecost BL, FitzGerald MG, Malins JM (1975) Myocardial infarction in diabetics. Quart J Med 44: 125-132
108. Kereiakes DJ (1985) Myocardial infarction in the diabetic patients. Clin Cardiol 8: 446-450
109. Cacciapuoti F, Spiezia R, Bianchi U, Lama D, D'Avino M, Varricchio M (1991) Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in noninsulin-dependent diabetes mellitus. Am J Cardiol 67: 843-847
110. Yudkin J, Oswald G (1988) Determinants of hospital admission and case fatality in diabetic patients with myocardial infarction. Diabetes Care 11: 351-358
111. Ohneda A, Maruhama Y, Itabashi H et al. (1978) Vascular complications and long-term administration of oral hypoglycemic agents in patients with diabetes mellitus. Tohoku J Exp Med 124: 205-222
112. Paasikivi J, Wahlberg F (1971) Preventive tolbutamide treatment and arterial disease in mild hyperglycaemia. Diabetologia 7: 323-327
113. Jarrett RJ, Chlouverakis C, Boyns DR (1968) The effect of treatment of moderate hyperglycaemia on the incidence of arterial disease. Postgrad Med J [Suppl]: 960-965
114. Jarrett RJ, McCartney P, Keen H (1982) The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 22: 79-84
115. Pogatsa G, Koltai MZ, Jermendy G, Simon J, Aranyi Z, Ballagi Pordany G (1992) The effect of sulphonylurea therapy on the outcome of coronary heart diseases in diabetic patients. Acta Med Hung 49: 39-51
116. Malmberg K, Ryden L, Efendic S, Herlitz J (1995) Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 26: 57-65
117. Dunn FL, Raskin P, Bilheimer DW, Grundy SM (1984) The effect of diabetic control on very low-density lipoprotein triglyceride metabolism in patients with type 2 diabetes mellitus and marked hypertriglyceridemia. Metabolism 33: 117-123
118. Taskinen MR, Beltz WF, Harper I et al. (1986) Effects of NIDDM on very low-density lipoprotein triglyceride and apolipoprotein B metabolism: studies before and after sulfonylurea therapy. Diabetes 35: 1268-1277
119. Moorhhouse JA (1967) A comparison of the effects of tolazamide and tolbutamide upon blood glucose and serum insulin and lipid levels in diabetic subjects. Can Med Assoc J 96: 536-539
120. Taskinen MR (1990) Hyperlipidemia in diabetes. Ballieres Clin Endocrinol Metabol 4: 743-775
121. Lisch HJ, Sailer S (1981) Lipoprotein patterns in diet, sulfonylurea, and insulin-treated diabetics. Diabetologia 20: 118-122
122. Calvert GD, Graham JJ, Mannik T, Wise PH, Yeates RA (1978) Effects of therapy on plasma high-density-lipoprotein-cholesterol concentration in diabetes mellitus. Lancet 2: 66-68
123. Huupponen RK, Viikari JS, Saarimaa H (1984) Correlation of serum lipids with diabetes control in sulfonyurea-treated diabetic patients. Diabetes Care 7: 575-578
124. Greenfield MS, Doberne L, Rosenthal M, Vreman HJ, Reaven GM (1982) Lipid metabolism in non-insulin dependent diabetes mellitus: effects of glipizide therapy. Arch Intern Med 42: 1498-1500
125. Stenman S, Groop PH, Saloranta C, Tötterman K, Fyhrqvist F, Groop L (1988) Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents. Diabetologia 31: 206-213
126. Osei K, O'Dorisio TM, Falko JM (1984) Concomitant insulin and sulfonylurea therapy in patients with type 2 diabetes: effects on glycoregulation and lipid metabolism. Am J Med 77: 1002-1009
127. Colwell JA (1991) Pathophysiology of vascular disease in diabetes: effects of gliclazide. Am J Med 90 [Suppl 6A]: 50S-54S
128. Fearnley GR, Chakrabarti R, Vincent CT (1960) Effect of sulfonylureas on fibrinolysis. Lancet II: 622-625
129. Aimer LO (1984) Effect of chlorpropamide and gliclazide on plasminogen activator activity in vascular walls in patients with maturity onset diabetes. Thromb Res 35: 19-25
130. Gram J, Jespersen J (1991) Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients. Am J Med 90: 62S-66S
131. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS (1993) Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med 10: 27-32
132. Jennings PE, Scott NA, Santabadi AR, Belch JJF (1992) Effects of gliclazide on platelet reactivity and free radicals in type 2 diabetic patients: clinical assessments. Metabolism 41: 36-39
133. Nair CH, Azhar A, Wilson JD, Dhall DP (1991) Studies on fibrin network structure in human plasma. Part 2, clinical application: diabetes and antidiabetic drugs. Thrombosis Res 64: 477-485
134. Klaff LJ, Kernoft L, Vinik AI, Jackson WPU (1981) Sulfonylureas and platelet function. Am J Med 70: 627-630
135. Violoi F, Mattia GC, Alessandri C, Perrone A, Vezza E (1982) Effects of gliclazide and glibenclamide on platelet function, fibrinolysis and metabolic control in diabetic patients with retinopathy (author's transl). Curr Med Res Opin 8: 200-203
136. Fu ZZ, Yan T, Chen YJ, Sang JQ (1992) Thromboxane/ prostacyclin balance in type 2 diabetes: gliclazide effects. Metabolism 41 [Suppl 1]: 33-35
137. Marquie G (1978) Preventive effect of gliclazide on experimental atherosclerosis in rabbits. Diabetologia 14: 269-275
138. Sobenin IA, Maksumova MA, Slavina ES, Balabolkin MI, Orehkhov AN (1994) Sulfonylureas induce cholesterol accumulation in cultured human intimal cells and macrophages. Atherosclerosis 105: 159-163
139. Paton RC, Kernoff PB, Wales JK, McNicol GP (1981) Effects of diet and gliclazide on the haemostatic system of non-insulin-dependent diabetics. BMJ 283: 1018-1020
140. U.K. Prospective Diabetic Study Group (1995) U.K. Prospective Diabetes Study 16. Overview of 6 years therapy of type II diabetes: a progressive disease. Diabetes 44: 1249-1258